[Effect of bromocryptin in polycystic ovary syndrome].
Ten patients with polycystic ovarian disease and normoprolactinemia received bromocriptine 5 mg daily for up to 4 months. The following parameters were evaluated before treatment and at monthly intervals menstrual patterns, hirsutism score, weight, and blood pressure and LH, FSH, prolactine, unbound and total testosterone in plasma. In 5 out of 10 subjects with oligomenorhea or amenorhea normal menstruations were observed; 3 additional subjects got more frequent but not normal menstruation and 2 patients got pregnant. No changes in LH, FSH and androgens were observed. Prolactin levels fell significantly in all subjects. No clinical nor biochemical parameter predicted the improvement in menstrual patterns. Bromocriptine may have a place in the treatment of polycystic ovarian diseases with normoprolactinemia though its mechanism of action is unclear.
Fuhrer
J
J
Servicio de Obstetricia y Ginecología, Hospital San José.
Cheviakoff
S
S
Rubio
V
V
D000293:Adolescent; D000328:Adult; D001971:Bromocriptine / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008599:Menstruation Disturbances / Q000209:etiology; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011247:Pregnancy; D011248:Pregnancy Complications; D011388:Prolactin / Q000097:blood; D011446:Prospective Studies; D013739:Testosterone / Q000097:blood
D001971:Bromocriptine; D013739:Testosterone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone
Efecto de la bromocriptina en el síndrome de ovario poliquístico.